Biopharma M&A on Pace for Best Year Since Pre-Pandemic Peak

Global biopharma dealmaking is surging toward its strongest year since 2019, with $106 billion in transactions across 201 deals recorded so far in 2026, according to PitchBook data. If the current pace holds, total deal value could exceed $250 billion by year-end.

The acceleration follows a post-pandemic trough in 2022 and a softer 2024, when total deal value fell to $114.8 billion, before rebounding sharply to $209 billion in 2025. Pharma companies are "really buying stuff like it's going out of fashion," said Rajesh Kumar, head of life sciences and healthcare equity research at HSBC, though he noted that the dealmaking environment in the first half of the year was somewhat more favorable than current conditions, given rising interest rates linked to inflationary pressures following the Iran conflict.

The dominant trend is the so-called bolt-on acquisition, typically in the $1 billion to $5 billion range, targeting specific products rather than entire franchises. Nanna Lüneborg, general partner at life sciences venture capital firm Forbion, cited GSK's (GSK) recent $2.2 billion acquisition of RAPT Therapeutics as representative of the approach. Smaller deals carry fewer integration risks and attract less antitrust scrutiny than the mega-mergers of prior cycles, she said. Average deal value has nonetheless climbed to $527.3 million so far in 2026, up from $365 million last year.

The underlying driver remains the patent cliff facing much of the industry. "You still need to fill the hole in your P&L when the patent cliffs hit," Kumar said. The dynamic is creating a bifurcated landscape: companies with strong growth trajectories, such as Eli Lilly (LLY), attract willing partners, while those facing steeper exclusivity losses must be more proactive in sourcing assets.

That search has increasingly led Western pharma to China. Despite shifting U.S. draft regulations on the use of Chinese clinical data, interest in acquiring Chinese-originated assets remains strong. A so-called NewCo model has emerged, in which ex-China rights are acquired to establish new companies in Europe or the U.S. to navigate FDA and EMA approval processes. Lüneborg described it as a mutually beneficial arrangement for Chinese biotechs with compelling science but limited global infrastructure.

Broader market conditions have also turned supportive. The biotech index XBI has risen 50% over the past 12 months, and the IPO window has reopened, drawing generalist investors back into the sector. Active therapeutic areas include oncology, metabolic disease, and central nervous system conditions, including Alzheimer's disease.